The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells

Menopause

Volumn 18, Issue 8, 2011, Pages 845-850

  Neubauer, Hans ^a   Yang, Yang ^a   Seeger, Harald ^a   Fehm, Tanja ^a   Cahill, Michael A ^b   Tong, Xiaowen ^c   Ruan, Xiangyan ^d   Mueck, Alfred O ^a  

^a University Women's Hospital   (Germany)

^b CHARLES STURT UNIVERSITY   (Australia)

^c TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer cells; Estradiol; Progesterone receptor membrane component 1; Progestogens; Proliferative response

Indexed keywords

ESTRADIOL; FULVESTRANT; MEDROXYPROGESTERONE ACETATE; PROGESTERONE; PROGESTERONE DERIVATIVE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; ORAL CONTRACEPTION; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CONTRACEPTIVE AGENTS, FEMALE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; FEMALE; HUMANS; MEDROXYPROGESTERONE ACETATE; MEMBRANE PROTEINS; RECEPTORS, PROGESTERONE;

EID: 80051548985     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31820e5ac5     Document Type: Article

References (24)

1. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:S1-S66.
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
3. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004;291:1701-1712.
4. Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-1299. (Pubitemid 28433474)
5. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk? J Clin Oncol 2006;24:1823-1830. (Pubitemid 46638979)
6. Tamimi RM, Byme C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-1187. (Pubitemid 47233068)
7. Schneider J, Martin-Gutiérrez S, Tresguerres JA, Garcia-Valesco JA. Circulating estradiol defines the tumor phenotype in menopausal breast cancer. Maturitas 2009;64:43-45.
8. Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev 2009;18:169-176.
9. Rock CL, Flatt SW, Laughlin GA, et al. Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev 2008;17:614-620. (Pubitemid 351469211)
10. Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 1998;90:37-42. (Pubitemid 28078079)
11. Lagiou P, Georgila C, Samoli E, et al. Estrogen > and progesterone receptor expression in the normal mammary epithelium in relation to breast cancer risk. Int J Cancer 2009;124:440-442.
12. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105:16-36. (Pubitemid 47211947)
13. Neubauer H, Clare SE, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008;10:R85.
14. Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;3:230-239.
15. Neubauer H, Chen R, Schneck H, et al. Membrane-initiated effects of progestogens on proliferation and downstream signal cascades in MCF-7 breast cancer cells. Submitted for publication.
16. Meyer C, Schmid R, Scriba PC, Wehling M. Purification and partial sequencing of high-affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996;239:726-733.
17. Munton RP, Tweedie-Cullen R, Livingstone-Zatchej M, et al. Qualitative and quantitative analyses of protein phosphorylation in naive and stimulated mouse synaptosomal preparations. Mol Cell Proteomics 2007;6: 283-293. (Pubitemid 46359516)
18. Ahmed IS, Rohe HJ, Twist KE, Craven RJ. PGRMC1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010;285: 24775-24782.
19. Hughes AL, Powell DW, Bard M, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007;5:143-149. (Pubitemid 46172917)
20. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab 2008;93: 1592-1599. (Pubitemid 351656493)
21. Peluso JJ, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008;149:534-543. (Pubitemid 351159360)
22. Crudden G, Chitti RE, Craven RJ. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J Pharmacol Exp Ther 2006;316:448-455. (Pubitemid 41832625)
23. Opatrny L, Dell'Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. Br J Obstet Gynecol 2008;115:169-175. (Pubitemid 350233601)
24. Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising noninvasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997;76:494-501. (Pubitemid 27331215)